08:49 AM EDT, 10/03/2024 (MT Newswires) -- (Updates with Eli Lilly's ( LLY ) response in the last two paragraphs.)

Eli Lilly's ( LLY ) tirzepatide injection is no longer considered to be in short supply in the US, the US Food and Drug Administration said in a notice Wednesday.

Tirzepatide injection had been in shortage since 2022 due to higher demand, the FDA added.

The FDA said that the regulator confirmed with the drug's producer that their product availability and production capacity can match the current and estimated national demand.

"Patients and prescribers may still see intermittent localized supply disruptions as the products move through the supply chain from the manufacturer and distributors to local pharmacies," according to the regulator.

Tirzepatide is sold under the brand names Mounjaro to treat diabetes and Zepbound for weight loss treatment.

Eli Lilly ( LLY ) said some supply snags may persist. "The supply chain is complex, especially for refrigerated medicines, and there may be many reasons why a particular pharmacy does not have a particular dose of the medicine in stock," the company said.

Executive Vice President Patrik Jonsson said the company "invested significantly to expand manufacturing and bring new options to the market."

Price: 894.01, Change: +2.94, Percent Change: +0.33